Liposome-stabilized oil-in-water emulsions as adjuvants: Increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen

Immunology and Cell Biology

Volumn 82, Issue 5, 2004, Pages 531-538

  Richards, Roberta L ^a   Rao, Mangala ^a   Vancott, Thomas C ^b,c   Matyas, Gary R ^a   Birx, Deborah L ^a   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

Adjuvant; CTL; Emulsion; HIV; Liposomes

Indexed keywords

GLYCOPROTEIN GP 140; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; LIPID A; LIPOSOME; OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG STABILITY; EMULSION; ENCAPSULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; DRUG STABILITY; EMULSIONS; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP160; IMMUNOGLOBULIN G; LIPOSOMES; MICE; MICE, INBRED BALB C; OILS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; WATER;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 7044265093     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0818-9641.2004.01282.x     Document Type: Article

References (31)

1. Muderhwa JM, Matyas GR, Spitler LE, Alving CR. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J. Pharmaceut. Sci. 1999; 88: 1332-9.
2. Gupta RK, Siber GR. Adjuvants for human vaccines: current status, problems and future prospects. Vaccine 1995; 13: 1263-76.
3. Hilleman MR. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog. Medical Virol. 1966; 8: 131-82.
4. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 1980; 2: 370-83.
5. Phillips NC. Liposomal carriers for the treatment of acquired immune deficiency syndromes. Bull. Institute Pasteur 1992; 90: 205-30.
6. Alving CR, Wassef NM. Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation. AIDS Res. Human Retroviruses 1994; 10: S91-4.
7. Alving CR, Koulchin V, Glenn GM, Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 1995; 145: 5-31.
8. Norris PJ, Rosenberg ES. Cellular immune response to human immunodeficiency virus. AIDS 2001; 15: S16-21.
9. Jäger D, Jäger E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 2001; 54: 669-74.
10. White K, Krzych U, Gordon DM et al. Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes. Vaccine 1993; 11: 1341-6.
11. Heppner DG, Gordon DM, Gross M et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 1996; 174: 361-6.
12. Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc. Natl Acad. Sci. USA 1991; 88: 3300-4.
13. VanCott TC, Mascola JR, Kaminski RW et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 1997; 71: 4319-30.
14. VanCott TC, Kaminski RW, Mascola JR et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 1998; 160:2000-12.
15. Kalyanaraman VS, Pal R, Gallo RC, Sarngadharan MG. A unique human immunodeficiency virus culture secreting soluble gp160. AIDS Res. Human Retroviruses 1988; 4: 319-29.
16. Kalyanaraman VS, Rodriguez V, Veronese F et al. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res. Human Retroviruses 1990; 6:371-80.
17. White WI, Cassait DR, Madsen J et al. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 1995; 13: 1111-22.
18. Berzofsky JA. Development of artificial vaccines against HIV using defined epitopes. FASEB J. 1991; 5: 2412-18.
19. Alving CR, Shichijo S, Mattsby-Baltzer I, Richards RL, Wassef NM. Preparation and use of liposomes in immunological studies. In: Gregoriadis G (ed.). Liposome Technology, vol. 3. Boca Raton: CRC Press, 1993; 317-43.
20. Matyas GR, Mudherwa JM, Alving CR. Oil-in-water liposomal emulsions for vaccine delivery. Meth. Enzy. 2003; 373: 34-50.
21. Herbert WJ. The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunology 1968; 14: 301-18.
22. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993; 11: 293-306.
23. Ott G, Radhakrishnan R, Fang J-H, Hora M. The adjuvant MF59: a 10-year perspective. Meth. Mol. Med. 2000; 42: 211-28.
24. Woodard LF, Jasman RL. Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants. Vaccine 1985; 3: 137-44.
25. Singh M, Hioe C, Qiu H et al. CTL induction using synthetic peptides delivered in emulsions-critical role of the formulation procedure. Vaccine 1997; 15: 1773-8.
26. Nicklas W. Aluminum salts. Res. Immunol 1992; 143: 489-94.
27. Harris DT, Matyas GR, Gomella LG et al. Immunologic approaches to the treatment of prostate cancer. Semin. Oncol. 1999; 26: 439-47.
28. Rao M, Alving CR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv. Drug Deliv. Rev. 2000; 41: 171-88.
29. Alving CR. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002; 20: S56-S64.
30. McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Sem. Cancer Biol. 1995; 6: 375-85.
31. Stoute JA, Slaoui M, Heppner G et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New Engl. J. Med. 1997; 336: 86-91.